"Bardoxolone methyl activates Keap1-Nrf2 and increases glutathione levels in cultured cells" by Ron Bumeister, Ph.D., Senior Scientist, Reata Pharmaceuticals
"Bardoxolone methyl improves markers of endothelial function in cultured cells" by Deborah A. Ferguson, Ph.D., Director, Discovery Biology, Reata Pharmaceuticals
"Treatment with Nrf2 activator ameliorates uremia-induced oxidative stress, endothelial dysfunction, and hypertension" by Stanislav Shelkovnikov, Ph.D., Associate Researcher, University of California, Irvine
"Treatment with an AIM increases GFR monitored by inulin clearance in rats" by W. Christian Wigley, Ph.D., Vice President, Research, Reata Pharmaceuticals
"Targeting Keap1-Nrf2 pathway ameliorates renal inflammation and fibrosis in mice with protein-overload proteinuria" by Carlamaria Zoja, Ph.D., Head, Laboratory of Experimental Models of Kidney Diseases, Mario Negri Institute for Pharmacological Research
"Effects of bardoxolone methyl on renal protein handling and secondary nephropathy" by Irina Dulubova, Ph.D., Director, Biochemistry and Structural Biology, Reata Pharmaceuticals
About Bardoxolone Methyl
Bardoxolone methyl is an antioxidant inflammation modulator (AIM) that activates Nrf2, thereby inducing the transcription of more than 250 genes that decrease the level of oxidative stress and suppress important inflammatory mediators. In two Phase 2a studies, bardoxolone methyl was shown to produce a statistically significant increase in kidney function in patients with moderate to severe CKD and Type 2 diabetes.
About Chronic Kidney Disease and Diabetic Kidney Disease (Nephropathy)
CKD is a highly prevalent condition, affecting more than 50 million adults around the world. Diabetes is the leading cause of CKD, with as many as 30 to 40 percent of Type 2 diabetics developing the disease. Available therapies modestly slow the progression o
|SOURCE Reata Pharmaceuticals|
Copyright©2010 PR Newswire.
All rights reserved